Epcoritamab + Lenalidomide + Tafasitamab for Lymphoma
(ECLAT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new combination of three drugs to determine their safety and effectiveness in treating certain types of lymphoma that have returned or are unresponsive to treatment. The drugs under investigation are epcoritamab, lenalidomide, and tafasitamab. Individuals who have undergone at least two previous unsuccessful treatments for their lymphoma may be suitable candidates for this trial. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group, providing an opportunity to potentially benefit from an innovative therapy.
Do I need to stop my current medications to join the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss your specific medications with the trial team to get a clear answer.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
A previous study found the combination of tafasitamab and lenalidomide to be generally safe for patients with large B-cell lymphoma. While some patients experienced side effects, the treatment was mostly well-tolerated. About 54% of patients had at least one significant side effect, with neutropenia, a low white blood cell count, being the most common. Doctors can monitor and manage this condition.
Epcoritamab, when combined with other treatments, has shown positive effectiveness. However, specific safety information for its combination with tafasitamab and lenalidomide is not detailed in the sources. Since tafasitamab and lenalidomide have been well-studied and the trial is in Phase 2, some established safety evidence exists. This suggests the combination is expected to be relatively safe, though side effects should be monitored. Always consult a healthcare provider to understand the risks.12345Why are researchers excited about this trial's treatments?
Researchers are excited about the combination of Epcoritamab, Lenalidomide, and Tafasitamab for lymphoma because it offers a unique multi-pronged approach to tackling cancer cells. Unlike standard treatments, Epcoritamab is a bispecific antibody that targets CD3 and CD20, potentially enhancing the body's immune response directly against lymphoma cells. Tafasitamab, another antibody, targets CD19, adding another layer of attack on the cancer. Meanwhile, Lenalidomide boosts the immune system and attacks cancer cells, offering a comprehensive strategy that could improve outcomes compared to existing therapies. This combination may provide a more robust and targeted assault on lymphoma, which is why it's generating excitement in the medical community.
What evidence suggests that this trial's treatments could be effective for DLBCL?
Research has shown that using tafasitamab and lenalidomide together can effectively treat certain types of lymphoma. One study found that 57.5% of patients experienced a reduction or disappearance of their cancer, with many achieving a complete response, meaning no signs of cancer were found. In this trial, participants will receive a combination of epcoritamab, lenalidomide, and tafasitamab. Epcoritamab, when combined with lenalidomide and another drug, has demonstrated even better results in similar cases, significantly reducing the cancer. These findings suggest that this combination could be promising for people with relapsed or difficult-to-treat lymphoma.13467
Who Is on the Research Team?
Pallawi Torka, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
This trial is for people with Diffuse Large B Cell Lymphoma (DLBCL) who have tried other treatments that didn't work or the disease came back. Specific details about eligibility criteria are not provided, but typically participants need to meet certain health standards and may be required to follow specific protocols.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Epcoritamab subcutaneously once weekly in cycles 1-3 and every 4 weeks in cycles 4-12, Tafasitamab intravenously once weekly during cycles 1-3 and every 2 weeks during cycles 4-12, and Lenalidomide orally daily on days 1-21 of a 28-day cycle
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Epcoritamab
- Lenalidomide
- Tafasitamab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Incyte Corporation
Industry Sponsor
Steven Stein
Incyte Corporation
Chief Medical Officer since 2015
MD from University of Witwatersrand
Hervé Hoppenot
Incyte Corporation
Chief Executive Officer since 2014
MBA from ESSEC Business School
Genmab
Industry Sponsor
Dr. Jan van de Winkel
Genmab
Chief Executive Officer since 2010
PhD in Immunology, University of Utrecht
Dr. Judith Klimovsky
Genmab
Chief Medical Officer since 2019
MD, University of Copenhagen